The use of transgenic mice in pharmacokinetic and pharmacodynamic studies
- 1 April 2001
- journal article
- review article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 90 (4) , 422-435
- https://doi.org/10.1002/1520-6017(200104)90:4<422::aid-jps1001>3.0.co;2-z
Abstract
No abstract availableKeywords
This publication has 71 references indexed in Scilit:
- Antinociceptive effects of morphne-6-glucuronide in homozygous MDR1a P-glycoprotein knockout and in wildtype mice in the hotplate testLife Sciences, 2000
- Development of an In Situ Mouse Brain Perfusion Model and its Application to mdr1a P-Glycoprotein-Deficient MiceJournal of Cerebral Blood Flow & Metabolism, 2000
- Genetic Models for Non Insulin Dependent Diabetes Mellitus in RodentsJournal of Basic and Clinical Physiology and Pharmacology, 1998
- Role of CYP1A2 in caffeine pharmacokinetics and metabolism: studies using mice deficient in CYP1A2Pharmacogenetics, 1996
- Conditional gene targeting.Journal of Clinical Investigation, 1996
- Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.Journal of Clinical Investigation, 1995
- Inducible Gene Targeting in MiceScience, 1995
- Transgenic Animals in ToxicologyFundamental and Applied Toxicology, 1994
- Intravascular distribution of zidovudine: Role of plasma proteins and whole blood componentsAntiviral Research, 1993
- Transgenic animals as tools in drug developmentInflammation Research, 1993